Financials data is unavailable for this security.
View more
Year on year Edwards Lifesciences Corp 's net income fell -7.85% from 1.52bn to 1.40bn despite revenues that grew 11.56% from 5.38bn to 6.00bn. An increase in the cost of goods sold as a percentage of sales from 20.07% to 22.98% was a component in the falling net income despite rising revenues.
Gross margin | 77.58% |
---|---|
Net profit margin | 25.17% |
Operating margin | 26.77% |
Return on assets | 15.14% |
---|---|
Return on equity | 21.00% |
Return on investment | 17.44% |
More ▼
Cash flow in USDView more
In 2023, Edwards Lifesciences Corp increased its cash reserves by 48.59%, or 375.40m. The company earned 895.80m from its operations for a Cash Flow Margin of 14.92%. In addition the company generated 173.80m cash from investing, though they paid out 711.00m more in financing than they received.
Cash flow per share | 2.62 |
---|---|
Price/Cash flow per share | 25.64 |
Book value per share | 12.35 |
---|---|
Tangible book value per share | 9.74 |
More ▼
Balance sheet in USDView more
Current ratio | 3.71 |
---|---|
Quick ratio | 2.87 |
Total debt/total equity | 0.0803 |
---|---|
Total debt/total capital | 0.0737 |
More ▼
Growth rates in USD
SmartText is unavailable
EPS growth(5 years) | 14.85 |
---|---|
EPS (TTM) vs TTM 1 year ago | 13.30 |